Pharmacokinetics of Gepotidacin in Renal Impairment

Gepotidacin is a novel triazaacenaphthylene bacterial topoisomerase inhibitor. In this phase 1, nonrandomized, open‐label, parallel‐group, multicenter, multipart study, the pharmacokinetics, safety, and tolerability of a single intravenous (IV) dose of gepotidacin 750 mg over 2 hours were evaluated...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Pharmacol Drug Dev
Päätekijät: Hossain, Mohammad, Tiffany, Courtney, Raychaudhuri, Aparna, Nguyen, Dung, Tai, Guoying, Alcorn, Harry, Preston, Richard A., Marbury, Thomas, Dumont, Etienne
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2020
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7384084/
https://ncbi.nlm.nih.gov/pubmed/32429000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.807
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia